Eurofins Scientific (EUFI.PA), the global leader in bio-analytical testing, and one of the world leaders in genomic services, announces that it has acquired PerkinElmer, Inc.’s U.S. prenatal screening laboratory services business PerkinElmer Labs/NTD (“NTD”).
Founded more than 30 years ago, NTD is a reference laboratory in the US for first and second trimester prenatal screening. It has pioneered the research and development of prenatal screening protocols and offered the first biochemical screening test for early onset preeclampsia. NTD’s first trimester noninvasive prenatal screening test for Down Syndrome is the only high sensitivity screen that uses the free Beta hCG biomarker, along with PAPP-A and Nuchal Translucency measurement, in assessing risk for Down syndrome.
The company generated revenues of about US$ 20m in 2015 and employs approximately 80 staff at its laboratory in Melville, NY, serving universities, hospitals, maternal fetal medicine specialists, and other laboratories worldwide.
The acquisition of NTD strengthens Eurofins’ growing footprint in the genetics segment of the specialty clinical diagnostic testing market. NTD’s expertise in reproductive genetic testing is fully complementary to the Group’s leading position in expanded carrier testing capabilities, and expands Eurofins’ analytical portfolio for genetic disorders, established through the acquisition of Emory Genetics Laboratory (“EGL”) in 2015, a joint venture with Emory University. The addition of NTD into Eurofins’ laboratory network further strengthens the Group’s pharmaceutical and clinical service offering and advances its development into a leading presence in the specialty clinical testing services for hospitals, clinicians and pharmaceutical companies.
Comment from Dr. Gilles Martin, Eurofins CEO: “This acquisition reflects our strategy of expanding and strengthening our network of competence centers. NTD strengthens Eurofins’ testing capabilities for genetic disorders, and the Group’s footprint in the specialty clinical diagnostics market, with truly unique and innovative services with high positive impact for patient care. In combination with ViraCor and Diatherix for infectious diseases, Boston Heart for cardiovascular, and EGL for genetic diseases, NTD’s expertise in prenatal screening reinforces the Group’s position in advanced diagnostic testing to better serve the global healthcare community”.
Next Finance , April 2016